SCHEMBL4776208

SCHEMBL4776208

FC(F)(F)Oc1cccc(CNc2cc[c]cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
KCNN3 Q9UGI6 1/20 0.47
P2RX7 Q99572 1/20 0.44
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
CCNT1 O60563 1/20 0.43
MAPK14 Q16539 1/20 0.43
PIM1 P11309 2/20 0.42
GRM2 Q14416 1/20 0.42
CARM1 Q86X55 2/20 0.41
PRMT6 Q96LA8 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
CETP P11597 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
GPR39 O43194 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535976 0.81 KDM5A (0.48) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL28658102 0.80 ALDH1A1 (0.36) KDM5AKDM4CKDM5BKCNN3PIM1
SCHEMBL28662582 0.79 CCNA2 (0.36) KDM5AKDM4CKDM5BKCNN3CCNT1
SCHEMBL18525587 0.79 KDM5A (0.49) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL22102122 0.79 KDM5A (0.49) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL4778987 0.78 KDM5A (0.51) KDM5AKDM4CKDM5BROCK1CCNT1
SCHEMBL28658271 0.77 KDM5A (0.50) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL22102194 0.76 KDM5A (0.49) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL988776 0.76 FABP1 (0.58) MEN1KMT2A
SCHEMBL18525794 0.75 KDM5A (0.59) KDM5AKDM4CKDM5BROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A KDM5A 1275/4885KDM4C 2509/4885KDM5B 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.